Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 11, 2022
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
Edward Tenthoff Maintained (ARWR) at Buy with Decreased Target to $72 on, May 11th, 2022
Edward Tenthoff of Piper Sandler, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Buy with Decreased Target from $89 to $72 on, May 11th, 2022.
Edward has made no other calls on ARWR in the last 4 months.
There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, 0 agree with Edward's Rating of Hold.
This is the rating of the analyst that currently disagrees with Edward
- Madhu Kumar of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Wednesday, January 19th, 2022
